Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 25, 2009

Quantum Immunologics to Commercialize Auburn University’s Veterinary Cancer Immunotherapy

  • Quantum Immunologics (QI) entered into an agreement with Auburn University to bring its cancer immunotherapy to the veterinary market. An independently funded and jointly owned company will be formed to accomplish this goal.

    QI will provide corporate and administrative management of the new company as well as license its oncofetal antigen-based therapy to serve as the collaboration's underlying technology. The partnership will draw upon Auburn's companion animal oncology expertise along with its animal clinical trial experience.

    "This collaboration provides a best-of-both-worlds approach,” according to QI's CEO Chuck Broes. “We have a tremendous respect for Auburn's renowned veterinary institution and believe that this collaboration provides a natural synergy, allowing both parties to maximize one another's core competencies. We also believe that this initiative will allow QI to capitalize upon the significant veterinary market." QI anticipates that the new company will begin operations in mid-2010.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »